Trial Profile
A Phase II Protocol for the Use of Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Anti-tenascin monoclonal antibody 81C6 I-131 (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Bradmer Pharmaceuticals
- 27 May 2009 New trial record